Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 176   

Articles published

GSK 1,476.21 -0.79 (-0.05%)
price chart
Is GlaxoSmithKline plc's Dividend Safe?
GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has had a bad time of it this year, being charged with bribery in China and losing patent protection on blockbuster drug Advair, which accounted for �5bn worth of sales in 2013.
Will GlaxoSmithKline plc Be Back To Growth By 2016?
Investing in steadily-growing companies like GlaxoSmithKline has made it possible for many an investor to achieve millionaire status -- and you can do it too.
GlaxoSmithKline plc Is Best In Class When It Comes To Affordable Medicine
Moreover, Glaxo is rapidly closing in on producing the world's first malaria vaccine, after filing for regulatory approval in July.
Related articles »  
Recovering GlaxoSmithKline plc Won't Be Cheap For Much Longer
Pharmaceutical giant GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is one of those rock-solid stocks that you despair of being able to pick up at a bargain price.
GLAXOSMITHKLINE (NYSE:GSK) Ebola vaccine to be ready by end of year  WallStreet Scope
GlaxoSmithKline net earnings dips by 62% in Q3  pharmabiz.com
Related articles »  
Why GlaxoSmithKline plc And HSBC Holdings plc Can Be The FTSE 100′s ...
In the case of GlaxoSmithKline, it is currently restructuring its business and is attempting to slash �1 billion of costs over a three-year period, with around half of the savings expected to be delivered in 2016.
Related articles »  
Why Forecasts Are Falling At GlaxoSmithKline plc
The company's quarterly figures this year have been falling short of expectations too, and at the first-half stage Glaxo reported a 12% fall in core EPS at constant exchange rates, with the statutory reported figure down 14% - at real exchange rates ...
Why GlaxoSmithKline plc And Shire PLC Could Be The Perfect Pharmaceutical ...
So, with a potent mix of income, growth and value, GlaxoSmithKline and Shire could prove to be the perfect pharmaceutical partnership.
Can GlaxoSmithKline plc Beat The FTSE 100 In 2015?
Investors in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) have endured a challenging year thus far. Shares in the pharmaceutical major have fallen by 13% since the turn of the year, with bribery allegations and a subsequent fine of just under �300 million ...
GlaxoSmithKline plc Stock Rating Reaffirmed by Credit Suisse (GSK)  WKRB News
GlaxoSmithKline plc Given "Underperform" Rating at Credit Suisse (GSK)  Ticker Report
Related articles »  
GlaxoSmithKline plc Is Working Hard To Unlock Value For Investors
At first glance it seems as if GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is struggling. The company's shares have underperformed the FTSE 100 by around 13% over the past five years and earnings per share have fallen by 8% over the past five years.
Related articles »  
Should I Invest In GlaxoSmithKline Plc Now?
GlaxoSmithKline When I last wrote about pharmaceutical giant GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) back in August, the shares were at 1382p.
GlaxoSmithKline plc Receives "Sell" Rating from Liberum Capital (GSK)  WKRB News
Investor's Watch List � GlaxoSmithKline (NYSE:GSK), Liberty Global plc ...  Techsonian (press release)
Related articles »